Jointown(SH:600998) Shang Hai Zheng Quan Bao·2025-10-14 20:01Core Viewpoint - The announcement details the investment activities of Jiuzhoutong Pharmaceutical Group Co., Ltd. regarding entrusted financial management for the third quarter of 2025, highlighting the company's strategy to utilize idle funds for investment while ensuring operational liquidity and safety [2][4][12]. Investment Overview - The maximum balance of entrusted financial management for the third quarter of 2025 was 1.3 billion RMB, with a balance of 0 RMB at the end of the quarter [5][12]. - The company plans to use up to 4 billion RMB of idle funds for purchasing safe and liquid financial products, with individual investment periods not exceeding 12 months [2][8]. Investment Purpose - The purpose of the investment is to enhance the efficiency of fund utilization and generate investment returns without affecting the company's normal operational funding needs [4][12]. Funding Source - The funds for the entrusted financial management products in the third quarter of 2025 were sourced from the company's idle self-owned funds [6]. Investment Method - In the third quarter of 2025, the company used 5.4 billion RMB to purchase government bond reverse repos, with investment periods of 7 days and 5 days [7][8]. Risk Analysis and Control Measures - The investment scope primarily includes high-security, liquid, and capital-preserving financial products, with risks associated with market fluctuations and macroeconomic changes [3][9]. - The company has established risk management protocols, including selecting qualified financial institutions and maintaining oversight of investment activities [10]. Impact on the Company - The use of idle funds for entrusted financial management is designed to not disrupt the company's daily operations or main business activities, aiming to improve fund efficiency and yield better investment returns [12].